A Meta-Analysis of D-Cycloserine and the Facilitation of Fear Extinction and Exposure Therapy

Biological Psychiatry

Volumn 63, Issue 12, 2008, Pages 1118-1126

  Norberg, Melissa M ^a   Krystal, John H ^b   Tolin, David F ^a,b  

^a INSTITUTE OF LIVING   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; D cycloserine; exposure therapy; extinction; glutamate; neuroplasticity; NMDA

Indexed keywords

CYCLOSERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO;

ANXIETY DISORDER; AUTHOR; CLINICAL TRIAL; DATA BASE; DATA EXTRACTION; DEPENDENT VARIABLE; FEAR; FOLLOW UP; HUMAN; LANGUAGE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS; NERVE CELL PLASTICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REINFORCEMENT; REVIEW; SAMPLE SIZE; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; TRAINING; VELOCITY;

ANIMALS; ANXIETY DISORDERS; COMBINED MODALITY THERAPY; CYCLOSERINE; DESENSITIZATION, PSYCHOLOGIC; EXTINCTION, PSYCHOLOGICAL; FEAR; HUMANS; IMPLOSIVE THERAPY; NEURONAL PLASTICITY; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 44349151445     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.01.012     Document Type: Review

References (86)

1. Baker J.D., and Azorlosa J.L. The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behav Neurosci 110 (1996) 618-620
2. Royer S., and Pare D. Bidirectional synaptic plasticity in intercalated amygdala neurons and the extinction of conditioned fear responses. Neuroscience 115 (2002) 455-462
3. Cox J., and Westbrook R.F. The NMDA receptor antagonist MK-801 blocks acquisition and extinction of conditioned hypoalgesic responses in the rat. Q J Exp Psychol B 47 (1994) 187-210
4. Fanselow M.S., and LeDoux J.E. Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdala. Neuron 23 (1999) 229-232
5. Goosens K.A., and Maren S. Long-term potentiation as a substrate for memory: Evidence from studies of amygdaloid plasticity and Pavlovian fear conditioning. Hippocampus 12 (2002) 592-599
6. Rogan M.T., Staubli U.V., and LeDoux J.E. Fear conditioning induces associative long-term potentiation in the amygdala. Nature 390 (1997) 604-607
7. Davis M. Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: Clinical implications for exposure therapy. Eur J Neurosci 16 (2002) 395-398
8. D'Souza D.C., Charney D.S., and Krystal J.H. Glycine site agonists of the NMDA receptor: A review. CNS Drug Reviews 1 (1995) 227-260
9. Gomperts S.N., Rao A., Craig A.M., Malenka R.C., and Nicoll R.A. Postsynaptically silent synapses in single neuron cultures. Neuron 21 (1998) 1443-1451
10. Emmett M.R., Mick S.J., Cler J.A., Rao T.S., Iyengar S., and Wood P.L. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30 (1991) 1167-1171
11. Hood W.F., Compton R.P., and Monahan J.B. D-cycloserine: A ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98 (1989) 91-95
12. Watson G.B., Bolanowski M.A., Baganoff M.P., Deppeler C.L., and Lanthorn T.H. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510 (1990) 158-160
13. Krystal J.H. Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: New opportunities for synergy with psychotherapy. Biol Psychiatry 62 (2007) 833-834
14. Walker D.L., Ressler K.J., Lu K.T., and Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 22 (2002) 2343-2351
15. Ledgerwood L., Richardson R., and Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 117 (2003) 341-349
16. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61 (2004) 1136-1144
17. Hofmann S.G., Meuret A.E., Smits J.A., Simon N.M., Pollack M.H., Eisenmenger K., et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63 (2006) 298-304
18. Tolin DF, Pearlson GD, Krystal JH, Davis M, Meunier SA, Brady RS, et al. (2007): A controlled trial of d-cycloserine with brief CBT for panic disorder. Presented at the Annual Meeting of the World Congress of Behavioral and Cognitive Therapies, July 2007, Barcelona, Spain.
19. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al. (2008): D-cycloserine augmentation of behavior therapy for obsessive-compulsive disorder. Am J Psychiatry Epub ahead of print: February 1.
20. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 62 (2007) 835-838
21. Davis M., Myers K.M., Ressler K.J., and Rothbaum B.O. Facilitation of extinction of conditioned fear by d-cycloserine. Curr Dir Psychol Sci 14 (2005) 214-219
22. Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am Psychol 61 (2006) 741-756
23. Birk L. Pharmacotherapy for performance anxiety disorders: Occasionally useful but typically contraindicated. J Clin Psychol 60 (2004) 867-879
24. Davis M., Ressler K., Rothbaum B.O., and Richardson R. Effects of D-cycloserine on extinction: Translation from preclinical to clinical work. Biol Psychiatry 60 (2006) 369-375
25. Davis M., Walker D.L., and Myers K.M. Role of the amygdala in fear extinction measured with potentiated startle. Ann N Y Acad Sci 985 (2003) 218-232
26. Garakani A., Mathew S.J., and Charney D.S. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med 73 (2006) 941-949
27. Gillespie C.F., and Ressler K.J. Emotional learning and glutamate: Translational perspectives. CNS Spectrums 10 (2005) 831-839
28. Hofmann S.G. Enhancing exposure-based therapy from a translational research perspective. Behav Res Ther 45 (2007) 1987-2001
29. Hofmann S.G., Pollack M.H., and Otto M.W. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Reviews 12 (2006) 208-217
30. Otto M.W., Basden S., Leyro T.M., McHugh K.M., and Hofmann S.G. Clinical perspectives on the combination of d-cycloserine and CBT for the treatment of anxiety disorders. CNS Spectrums 12 (2007) 51-56 59-61
31. Richardson R., Ledgerwood L., and Cranney J. Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications. Learn Mem 11 (2004) 510-516
32. Glass G.V., McGaw B., and Smith M.L. Meta-Analysis in Social Research (1981), Sage Publications, London
33. Bailey J.E., Papadopoulos A., Lingford-Hughes A., and Nutt D.J. D-Cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology (Berl) 193 (2007) 579-585
34. Britton J.C., Gold A.L., Feczko E.J., Rauch S.L., Williams D., and Wright C.I. D-cycloserine inhibits amygdala responses during repeated presentations of faces. CNS Spectrums 12 (2007) 600-605
35. Gabriele A., and Packard M.G. D-Cycloserine enhances memory consolidation of hippocampus-dependent latent extinction. Learn Mem 14 (2007) 468-471
36. Port R.L., and Seybold K.S. Manipulation of NMDA-receptor activity alters extinction of an instrumental response in rats. Physiol Behav 64 (1998) 391-393
37. van den Bergh F.S., Bloemarts E., Groenink L., Olivier B., and Oosting R.S. Delay aversion: Effects of 7-OH-DPAT, 5-HT1A/1B-receptor stimulation and D-cycloserine. Pharmacol Biochem Behav 85 (2006) 736-743
38. Van Vleet T.M., Heldt S.A., Pyter B., Corwin J.V., and Reep R.L. Effects of light deprivation on recovery from neglect and extinction induced by unilateral lesions of the medial agranular cortex and dorsocentral striatum. Behav Brain Res 138 (2003) 165-178
39. VanVleet T.M., Heldt S.A., Guerrettaz K.R., Corwin J.V., and Reep R.L. Unilateral destruction of the dorsocentral striatum in rats produces neglect but not extinction to bilateral simultaneous stimulation. Behav Brain Res 136 (2002) 375-387
40. Bertotto M.E., Bustos S.G., Molina V.A., and Martijena I.D. Influence of ethanol withdrawal on fear memory: Effect of D-cycloserine. Neuroscience 142 (2006) 979-990
41. Botreau F., Paolone G., and Stewart J. D-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav Brain Res 172 (2006) 173-178
42. Kelley J.B., Anderson K.L., and Itzhak Y. Long-term memory of cocaine-associated context: Disruption and reinstatement. Neuroreport 18 (2007) 777-780
43. Akirav I. NMDA Partial agonist reverses blocking of extinction of aversive memory by GABA(A) agonist in the amygdala. Neuropsychopharmacology 32 (2007) 542-550
44. Yang Y.L., Chao P.K., Ro L.S., Wo Y.Y., and Lu K.T. Glutamate NMDA receptors within the amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. Neuropsychopharmacology 32 (2007) 1042-1051
45. Ledgerwood L., Richardson R., and Cranney J. D-cycloserine and the facilitation of extinction of conditioned fear: Consequences for reinstatement. Behav Neurosci 118 (2004) 505-513
46. Guastella A.J., Lovibond P.F., Dadds M.R., Mitchell P., and Richardson R. A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther 45 (2007) 663-672
47. Mao S.C., Hsiao Y.H., and Gean P.W. Extinction training in conjunction with a partial agonist of the glycine site on the NMDA receptor erases memory trace. J Neurosci 26 (2006) 8892-8899
48. Tomilenko R.A., and Dubrovina N.I. Effects of activation and blockade of NMDA receptors on the extinction of a conditioned passive avoidance response in mice with different levels of anxiety. Neurosci Behav Physiol 37 (2007) 509-515
49. Yang Y.L., and Lu K.T. Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala. Neuroscience 134 (2005) 247-260
50. Guastella A.J., Richardson R., Lovibond P.F., Rapee R.M., Gaston J.E., Mitchell P., and Dadds M.R. A randomised controlled trial of d-cycloserine enhancement of exposure therapy for social phobia. Biol Psychiatry 63 (2007) 544-549
51. Heimberg R.G., Horner K.J., Juster H.R., Safren S.A., Brown E.J., Schneier F.R., and Liebowitz M.R. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 29 (1999) 199-212
52. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. (1988), Lawrence Erlbaum Associates, Hillsdale, New Jersey
53. Rosenthal R. Meta-Analytic Procedures for Social Research (1991), Sage Publications, London
54. Storch E.A., Merlo L.J., Bengtson M., Murphy T.K., Lewis M.H., Yang M.C., et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 22 (2007) 230-237
55. Guastella A.J., Dadds M.R., Lovibond P.F., Mitchell P., and Richardson R. A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. J Psychiatr Res 41 (2007) 466-471
56. U.S. Food and Drug Administration. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (2005), U.S. Food and Drug Administration, Rockville, Maryland
57. Parnas A.S., Weber M., and Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 83 (2005) 224-231
58. Margraf J., Barlow D.H., Clark D.M., and Telch M.J. Psychological treatment of panic: Work in progress on outcome, active ingredients, and follow-up. Behav Res Ther 31 (1993) 1-8
59. Clark D.M., Salkovskis P.M., Hackmann A., Middleton H., Anastasiades P., and Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 164 (1994) 759-769
60. Brown T.A., and Barlow D.H. Long-term outcome in cognitive-behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment. J Consult Clin Psychol 63 (1995) 754-765
61. Davidson J.R., Foa E.B., Huppert J.D., Keefe F.J., Franklin M.E., Compton J.S., et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 61 (2004) 1005-1013
62. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162 (2005) 151-161
63. Barlow D.H., Gorman J.M., Shear M.K., and Woods S.W. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 283 (2000) 2529-2536
64. Marks I.M., Swinson R.P., Basoglu M., Kuch K., Noshirvani H., O'Sullivan G., et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 162 (1993) 776-787
65. Ledgerwood L., Richardson R., and Cranney J. D-cycloserine and the facilitation of extinction of conditioned fear: Consequences for reinstatement. Behav Neurosci 118 (2004) 505-513
66. Ledgerwood L., Richardson R., and Cranney J. D-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction. Biol Psychiatry 57 (2005) 841-847
67. Santini E., Muller R.U., and Quirk G.J. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci 21 (2001) 9009-9017
68. Weber M., Hart J., and Richardson R. Effects of D-cycloserine on extinction of learned fear to an olfactory cue. Neurobiol Learn Mem 87 (2007) 476-482
69. Randolph C., Roberts J.W., Tierney M.C., Bravi D., Mouradian M.M., and Chase T.N. D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 8 (1994) 198-205
70. Tuominen H.J., Tiihonen J., and Wahlbeck K. Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophr Res 72 (2005) 225-234
71. Goff D.C., Tsai G., Levitt J., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56 (1999) 21-27
72. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158 (2001) 1367-1377
73. Tsai G.E., Falk W.E., Gunther J., and Coyle J.T. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry 156 (1999) 467-469
74. Goff D.C., Herz L., Posever T., et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 179 (2005) 144-150
75. Duncan E.J., Szilagyi S., Schwartz M.P., Bugarski-Kirola D., Kunzova A., Negi S., et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 71 (2004) 239-248
76. Fakouhi T.D., Jhee S.S., Sramek J.J., Benes C., Schwartz P., Hantsburger G., et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol 8 (1995) 226-230
77. Laake K, Oeksengaard AR (2002): D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev (2):CD003153.
78. Boje K.M., Wong G., and Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 603 (1993) 207-214
79. Werner-Seidler A., and Richardson R. Effects of D-cycloserine on extinction: Consequences of prior exposure to imipramine. Biol Psychiatry 62 (2007) 1195-1197
80. Foa E.B., Hembree E.A., Cahill S.P., Rauch S.A., Riggs D.S., Feeny N.C., and Yadin E. Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: Outcome at academic and community clinics. J Consult Clin Psychol 73 (2005) 953-964
81. Lee J.L., Milton A.L., and Everitt B.J. Reconsolidation and extinction of conditioned fear: Inhibition and potentiation. J Neurosci 26 (2006) 10051-10056
82. Woods A.M., and Bouton M.E. D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. Behav Neurosci 120 (2006) 1159-1162
83. Wolpe J. The Practice of Behavior Therapy. 4th ed. (1990), Pergamon Press, New York
84. Mattick R.P., and Clarke J.C. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 36 (1998) 455-470
85. Shear M.K., Brown T.A., Barlow D.H., Money R., Sholomskas D.E., Woods S.W., et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154 (1997) 1571-1575
86. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46 (1989) 1006-1011